Chengdu Kangnuoxing Biopharma,inc.
Clinical trials sponsored by Chengdu Kangnuoxing Biopharma,inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot for teen hay fever? early trial underway Results expected Oct 2026 (estimated)
- New injection could tame teen hay fever Results expected Dec 2026 (estimated)
-
New shot could help patients with severe blistering skin disease ditch steroids
Disease control Not yet recruitingThis study tests an injection called stapokibart for people with moderate to severe bullous pemphigoid, a painful blistering skin condition. The goal is to see if it can help patients stop taking steroids and keep the disease under control for 36 weeks. About 200 adults aged 18 t…
Phase 3 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New shot for teen hay fever? early trial underway
Symptom relief Not yet recruitingThis phase 2 trial tests the safety of stapokibart injection in 15 teenagers aged 12-17 with seasonal allergic rhinitis (hay fever). Participants receive the drug alongside their usual allergy treatments. The study focuses on side effects and how the body processes the drug, not …
Phase 2 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New allergy shot under safety spotlight
Symptom relief Not yet recruitingThis study will test the safety of a new biologic drug called stapokibart, given as a shot, in 400 adults with seasonal allergic rhinitis (SAR). Participants are already prescribed the drug by their doctor. The main goal is to track any side effects. This is an open-label study, …
Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC